Related Experiment Videos

Basement membrane biosynthesis as a target to tumor therapy

M E Maragoudakis1, E Missirlis, M Sarmonika

  • 1Department of Pharmacology, University of Patras Medical School, Greece.

Insights

Tricyclodecan-9-yl-xanthate (D609) selectively kills tumor cells by inhibiting collagen synthesis and angiogenesis. This compound shows a dose-dependent antitumor effect in rats, suggesting basement membrane synthesis as a target for novel anti-angiogenic cancer therapies.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Tricyclodecan-9-yl-xanthate (D609) demonstrates selective tumor cell killing via an unelucidated mechanism.
  • Basement membrane collagen biosynthesis and angiogenesis are critical in tumor growth and metastasis.

Purpose of the Study:

  • To investigate the mechanism of action of D609.
  • To evaluate the anti-angiogenic and antitumor effects of D609.

Main Methods:

  • In vitro studies using chick chorioallantoic membrane to assess collagen biosynthesis and angiogenesis inhibition.
  • In vivo studies involving rats bearing Walker 256 carcinoma treated with D609.

Main Results:

  • D609 significantly inhibited basement membrane collagen biosynthesis in vitro.
  • D609 demonstrated anti-angiogenic activity in the chick chorioallantoic membrane model.
  • D609 treatment resulted in a dose-dependent reduction in tumor size in rats with Walker 256 carcinoma.

Conclusions:

  • D609's mechanism involves the inhibition of basement membrane collagen synthesis.
  • D609 exhibits promising anti-angiogenic and antitumor properties.
  • Targeting basement membrane synthesis represents a potential strategy for developing novel anti-angiogenic cancer therapeutics.

Related Concept Videos